Simpson Interventions Accepted into FDA's TAP Pilot Program for Breakthrough Device, Acolyte™ Catheter System
Only devices granted Breakthrough Device designation by the FDA may apply to enroll in the TAP Pilot Program.
- Only devices granted Breakthrough Device designation by the FDA may apply to enroll in the TAP Pilot Program.
- Simpson Intervention’s Acolyte Catheter System was recently designated as a Breakthrough Device on March 4, 2024.
- "Simpson Interventions is honored to be accepted into the FDA's TAP Pilot Program for our Acolyte Catheter System," said Dr. John B. Simpson, Ph.D., M.D., founder and CEO of Simpson Interventions.
- Simpson Interventions remains steadfast in its mission to bring transformative medical technologies to market, and the acceptance into the TAP Pilot Program marks a significant milestone in this journey.